Check 35,000+ stocks against 26 valuation models and 37 quality factors

Vikas Lifecare Limited (VIKASLIFE) fair value: what the stock is really worth

As of Oct 1, 2026: fair value of Vikas Lifecare Limited ₹0.97, price ₹1.20, upside -19.5%, quality 57 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? Yes
Add to watchlist

Consumer Defensive · IN · ISIN INE161L01027

VL Thin data Sep 27, 2026

Vikas Lifecare Limited

VIKASLIFE · NSE

Overvalued / MonitorQuality is not strong enough to offset the price risk.

!Fair value ₹0.9660 · Overvalued (−19.5%)

!Quality 57/100

✓Healthy Growth (revenue 5y +46.1 %/yr)

!Thin margins · 3.7% net margin (TTM)

✓Low debt · generates free cash flow

!Mixed vs. peers (7/12)

!Narrow moat 27/100

!Evidence only low, so the estimate is less certain

!Weak on valuation: 7 out of 100

!Weak on past: 14 out of 100

26 models, one by oneBear ₹0.7175 to bull ₹1.26 Growth analysisrevenue history, year by year Quality 57/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Vikas Lifecare Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range ₹1.06 – ₹7.90 · fair‑value band ₹0.7175 – ₹1.26 · the ₹1.20 price screens above the ₹0.9660 fair value. Dashed = 300-day average. As of Sep 27, 2026.

Follow Vikas Lifecare in your weekly email

Every Wednesday you see whether Vikas Lifecare is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Vikas Lifecare Limited engages in manufacturing and trading of polymers, chemicals, iron and steel, and plastic products in India and Ghana. The company operates through Real Estate Division; Trading & Manufacturing Division -Agro; Trading & Manufacturing Division -Polymers; and Trading Division -Infrastructure segments. It offers various polymer compounds, including PE compounds, PVC compounds, V blend SOE compounds, polypropylene compounds, and thermo plastic rubber (TPR) compounds. The company is involved in developing smart products comprising smart gas and water meters, and power distribution solutions; supplying of food grade piping systems for drinking water; infrastructure products consisting of drinking water pipes, fittings, and bars; trading of agro products, including rice and pulses; dealing in raw and finished cashew nuts, dry fruits, and other premium consumer products. In addition, it engages in research and development of horticultural, cultivation, and preservation and storage of agro products; aluminium foils; and processed food products. Further, the company is involved in the real estate activities. It also exports its products. The company was formerly known as Vikas Multicorp Limited and changed its name to Vikas Lifecare Limited in April 2021. Vikas Lifecare Limited was incorporated in 1995 and is based in Delhi, India.

Stock analysis

Vikas Lifecare Limited (VIKASLIFE) currently trades at ₹1.20, while our model-based Fair Value estimate is ₹0.9660, 19.5% below the price, so the stock looks overvalued today.

Valuation

Bull case: the Growth Earnings group reads highest at a median of ₹2.76 per share, and 17 of the 17 models we run sit above the ₹1.20 price.

Bear case: the Multiples group reads lowest at ₹1.68, and 0 of the 17 models stay below the price. Evidence for this calculation is low.

Scenario range: ₹0.7175 (bear) to ₹1.26 (bull), the price of ₹1.20 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 57/100 (solid quality), in the Consumer Defensive sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Vikas Lifecare Limited reported revenue of ₹5.0B in FY2026 versus ₹3.0B in FY2022, a compound +13.5%/yr. Reported net income was ₹184M in FY2026, compounding −10.5%/yr from FY2022.

Key figures

Market cap ₹2.7B (≈ $28.0M) · P/E ratio 12.0 · P/S ratio 0.44 · EPS (TTM) ₹0.1000 · Net margin 3.7% · Return on equity 3.4% · Return on assets (EBIT) −0.6% · Operating margin −16.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (medium confidence).

What moves the price

The share trades about 45% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Consumer Defensive peers we cover trades at 10% fair-value upside, at −20%, VIKASLIFE screens richer than that median.

Fair Value models

Bear ₹0.7175 Fair Value ₹0.9660 Bull ₹1.26

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹0.0510 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF ₹37.40 ₹57.72 ₹121.09 76

Growth DCF ₹35.10 ₹63.32 ₹118.54 75

5Y Revenue Exit ₹12.49 ₹16.92 ₹25.26 72

All 17 models by family

DCF Models

FCF DCF ₹37.40 ₹57.72 ₹121.09 76

Owner Earnings ₹1.96 ₹4.68 ₹10.16 70

5Y Revenue Exit ₹12.49 ₹16.92 ₹25.26 72

5Y P/E Exit ₹11.23 ₹16.14 ₹21.34 71

10Y Revenue Exit ₹19.71 ₹30.72 ₹36.49 68

10Y P/E Exit ₹18.94 ₹28.20 ₹41.21 63

Earnings-Based

Graham-Dodd ₹0.6700 ₹4.70 ₹6.59 63

Lynch FV ₹1.59 ₹2.28 ₹2.96 61

PEG = 1.0 ₹1.59 ₹2.28 ₹2.96 57

Multiples

P/E Multiple ₹1.26 ₹1.68 ₹2.11 63

P/S Multiple ₹1.26 ₹1.68 ₹2.11 58

P/B Multiple ₹1.26 ₹1.68 ₹2.11 55

EV/Revenue ₹2.56 ₹3.77 ₹4.97 53

Asset-Based

NCAV (Graham) ₹1.48 ₹1.99 ₹2.97 54

Growth DCF

Growth DCF ₹35.10 ₹63.32 ₹118.54 75

Economic Profit

Residual Income ₹2.14 ₹2.07 ₹2.11 71

Growth Earnings

Growth-Adj P/E ₹1.93 ₹2.76 ₹3.59 67

Open the full fair value analysis →

Notify me when VIKASLIFE reaches fair value

Put VIKASLIFE on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 57/100

Of which business quality 60 · Market factors (momentum, volatility) 32

Profitability 25

Margins and returns on capital today

Quality Growth 44

Are margins and returns improving?

Cashflow 100

Earnings quality: real cash, not paper profit

Fin. Strength 51

Balance sheet, leverage, solvency risk

Investment 38

Disciplined investing over empire-building

Low Volatility 74

Calm price path (market factor)

Momentum 18

Price trend over the last 3–12 months (market factor)

52W Momentum 6

Distance to the 52-week high (market factor)

Net Issuance 100

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 90/100

Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Revenue growth 1 year

+4.0%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+1.6%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+46.1%

Start year 2021 (pandemic). Over 10 years: +18.3% a year

Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+18.0%

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

’26

What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.

+6.3%

Earnings growth per share plus dividend.

Earnings per share, growth per year+6.3%

Dividend (yield on the price)0.0%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.6.3% vs 38.3%, slowing

Profit margin 2020 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → −11%

Start year 2021 (pandemic)

VIKASLIFE screens overvalued: fair value 20% below the price. Compare with Archer-Daniels-Midland Company →

Compare Vikas Lifecare Limited with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Farm Products · 279 stocks

Beats the industry median on 7/12 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 57 · Above median

Fair Value upside −19.5% · Below median

Profitability

Return on equity (TTM) 3.4% · Below median

Return on assets −3.8% · Bottom 25%

Net margin (TTM) 3.7% · Below median

Operating margin (TTM) −16.4% · Bottom 25%

Growth and dividend

Revenue growth 24.7% · Top 25%

Balance sheet

Debt / equity 0.09× · Below median

Valuation Multiplesvs Farm Products median · lower = cheaper

P/E (TTM) 12.0× · Cheaper than median

P/B 0.49× · Cheaper than median

P/S (TTM) 0.54× · Cheaper than median

P/FCF 0.6× · Cheapest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)7 · sector 26

FUTURE (revenue growth)100 · sector 23

PAST (return on equity)14 · sector 19

HEALTH (low debt)95 · sector 94

DIVIDEND (yield)0 · sector 44

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Farm Products stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Archer-Daniels-Midland Company ADM	$80.38	$38.02	−53%
Muyuan Foods Group 002714	¥40.48	¥115.35	+185%
Bunge Global SA BG	$108.14	$56.75	−48%
Tyson Foods, Inc TSN	$50.98	$37.06	−27%
Wens Foodstuff Group 300498	¥14.51	¥12.08	−17%
Mowi ASA MOWI	kr 205.60	kr 280.90	+37%
SalMar ASA SALM	kr 580.50	kr 171.05	−71%
Charoen Pokphand Foods Public Company CPF	21.80 THB	55.71 THB	+156%
United Plantations Berhad 2089	32.58 MYR	35.84 MYR	+10%
Fujian Wanchen Food Group 300972	¥155.26	¥254.63	+64%

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Vikas Lifecare Limited · Fair Value
₹0.9660 −20%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/VIKASLIFE" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Vikas Lifecare Limited · Fair Value</span><br><b style="font-size:20px">₹0.9660</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−20%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Vikas Lifecare Limited Fair Value". https://www.fairvalue-calculator.com/stock/VIKASLIFE

Frequently asked questions

Is Vikas Lifecare Limited (VIKASLIFE) overvalued or undervalued?

As of Sep 27, 2026, our model estimates a fair value of ₹0.9660 versus a price of ₹1.20, about −20% upside (overvalued).

What is the fair value of VIKASLIFE?

Our model-based fair value for Vikas Lifecare Limited is ₹0.9660 (as of Sep 27, 2026), built from audited fundamentals. The current price: ₹1.20.

What is the quality score of VIKASLIFE?

Vikas Lifecare Limited has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Vikas Lifecare Limited (VIKASLIFE)?

Our model-based price target is the fair value of ₹0.9660 (as of Sep 27, 2026) from 17 valuation models. Cautious scenario ₹0.7175, optimistic scenario ₹1.26. It is a calculation from audited fundamentals, not an analyst target.

What is the Vikas Lifecare Limited stock forecast for 2026?

Our models put fair value at ₹0.9660, about −20% upside versus a price of ₹1.20 (overvalued). Cautious scenario ₹0.7175, optimistic scenario ₹1.26. The calculation is refreshed regularly with new filings.

What is the revenue of Vikas Lifecare Limited (VIKASLIFE)?

Vikas Lifecare Limited reported trailing-twelve-month revenue of about ₹5.0B (latest available figure, as of Sep 27, 2026).

What is the intrinsic value of Vikas Lifecare Limited (VIKASLIFE)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vikas Lifecare Limited it is ₹0.9660 per share (as of Sep 27, 2026), against a price of ₹1.20. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).

Is Vikas Lifecare Limited stock overvalued or undervalued in 2026?

As of Sep 27, 2026, VIKASLIFE trades above its calculated fair value: price ₹1.20, fair value ₹0.9660, a gap of about −20% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of VIKASLIFE?

No. The price is what the market pays today (₹1.20); the fair value is what the company's own numbers justify (₹0.9660). For Vikas Lifecare Limited the two are ₹0.2340 per share apart. That gap is exactly why we show both numbers side by side.

How much is Vikas Lifecare Limited worth?

The market values Vikas Lifecare Limited at about ₹2.7B (market capitalisation, as of Sep 27, 2026). Per share that is ₹1.20; our models calculate a fair value of ₹0.9660 per share.

What do the bullish and bearish scenarios say about VIKASLIFE?

Our models span a range for Vikas Lifecare Limited: cautious scenario ₹0.7175, base ₹0.9660, optimistic ₹1.26 per share (as of Sep 27, 2026, price ₹1.20). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of VIKASLIFE?

Vikas Lifecare Limited trades at a price-to-earnings ratio of 12.0 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹0.9660 is built from several models across several years. Other multiples: P/B 0.5, P/S 0.5.

How solid is the balance sheet of Vikas Lifecare Limited (VIKASLIFE)?

Balance-sheet figures for Vikas Lifecare Limited (as of Sep 27, 2026): return on equity 3.4%, debt of 0.09 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.

How far is VIKASLIFE from its 52-week high?

Vikas Lifecare Limited trades at ₹1.20, about 45% below its 52-week high of ₹2.20 and 13% above the low of ₹1.06 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹0.9660 is for.

Which stocks are comparable to Vikas Lifecare Limited?

From the same area (Consumer Defensive) we also value Archer-Daniels-Midland Company, Muyuan Foods Group, Bunge Global SA, Tyson Foods, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Vikas Lifecare Limited stock attractive at the current price?

The data as of Sep 27, 2026: price ₹1.20, calculated fair value ₹0.9660 (−20%), Quality Score 57/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of VIKASLIFE calculated?

We run Vikas Lifecare Limited through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹0.9660, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. Vikas Lifecare Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Vikas Lifecare Limited (VIKASLIFE)?

The closing price on Oct 1, 2026 was ₹1.20. Our model-based fair value is ₹0.9660, about −20% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Vikas Lifecare Limited right now?

Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Vikas Lifecare Limited

How large is the market capitalisation of Vikas Lifecare Limited (VIKASLIFE)?

The market capitalisation of Vikas Lifecare Limited is ₹2.7B (≈ $28.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Vikas Lifecare Limited (VIKASLIFE)?

The price-to-sales ratio of Vikas Lifecare Limited is 0.44 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Vikas Lifecare Limited (VIKASLIFE)?

Earnings per share at Vikas Lifecare Limited are ₹0.1000 (price ÷ EPS = P/E 12.0). Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of Vikas Lifecare Limited (VIKASLIFE)?

The net margin of Vikas Lifecare Limited is 3.7% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Vikas Lifecare Limited (VIKASLIFE)?

The return on equity (ROE) of Vikas Lifecare Limited is 3.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Vikas Lifecare Limited (VIKASLIFE)?

On an EBIT basis the return on assets of Vikas Lifecare Limited is −0.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Vikas Lifecare Limited (VIKASLIFE)?

The operating margin of Vikas Lifecare Limited is −16.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Vikas Lifecare Limited (VIKASLIFE)?

Revenue at Vikas Lifecare Limited is growing +24.7% versus a year earlier (3y avg +1.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Vikas Lifecare Limited (VIKASLIFE)?

Earnings per share at Vikas Lifecare Limited are growing +233% versus a year earlier. How much earnings per share grew versus a year earlier.

How much free cash flow does Vikas Lifecare Limited (VIKASLIFE) generate?

The free cash flow of Vikas Lifecare Limited is ₹4.3B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net debt does Vikas Lifecare Limited (VIKASLIFE) carry?

The net debt of Vikas Lifecare Limited is ₹1.0B (fiscal year 2026, ≈ 0.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch Vikas Lifecare Limited in the live analysis

One click puts Vikas Lifecare Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.